145 related articles for article (PubMed ID: 9226107)
1. Liver MRI with contrast enhancement.
Runge VM
Crit Rev Diagn Imaging; 1997 Jun; 38(3):207-30. PubMed ID: 9226107
[TBL] [Abstract][Full Text] [Related]
2. Enhanced liver MR: contrast agents and imaging strategy.
Runge VM; Kirsch JE; Wells JW; Awh MH; Bittner DF; Woolfolk CE
Crit Rev Diagn Imaging; 1993; 34(1-2):1-30. PubMed ID: 8216813
[TBL] [Abstract][Full Text] [Related]
3. Liver. III: Gadolinium-based hepatobiliary contrast agents (Gd-EOB-DTPA and Gd-BOPTA/Dimeg).
Giovagnoni A; Paci E
Magn Reson Imaging Clin N Am; 1996 Feb; 4(1):61-72. PubMed ID: 8673717
[TBL] [Abstract][Full Text] [Related]
4. Contrast-enhanced magnetic resonance cholangiography with Gd-BOPTA and Gd-EOB-DTPA in healthy subjects.
Dahlström N; Persson A; Albiin N; Smedby O; Brismar TB
Acta Radiol; 2007 May; 48(4):362-8. PubMed ID: 17453513
[TBL] [Abstract][Full Text] [Related]
5. Contrast enhanced liver MRI in patients with primary sclerosing cholangitis: inverse appearance of focal confluent fibrosis on delayed phase MR images with hepatocyte specific versus extracellular gadolinium based contrast agents.
Husarik DB; Gupta RT; Ringe KI; Boll DT; Merkle EM
Acad Radiol; 2011 Dec; 18(12):1549-54. PubMed ID: 21958599
[TBL] [Abstract][Full Text] [Related]
6. [Evaluation of Gd-BOPTA and Gd-DTPA in contrast-enhanced MR imaging of the liver].
Zhang HM; Ouyang H; Zhou CW
Zhonghua Zhong Liu Za Zhi; 2006 Feb; 28(2):111-5. PubMed ID: 16750014
[TBL] [Abstract][Full Text] [Related]
7. [Hepatic and hepatocarcinoma magnetic resonance: comparison of the results obtained with paramagnetic (gadolinium) and superparamagnetic (iron oxide particles) contrast media].
Castoldi MC; Fauda V; Scaramuzza D; Vergnaghi D
Radiol Med; 2000 Sep; 100(3):160-7. PubMed ID: 11148882
[TBL] [Abstract][Full Text] [Related]
8. Liver vessel enhancement by Gd-BOPTA and Gd-EOB-DTPA: a comparison in healthy volunteers.
Brismar TB; Dahlstrom N; Edsborg N; Persson A; Smedby O; Albiin N
Acta Radiol; 2009 Sep; 50(7):709-15. PubMed ID: 19701821
[TBL] [Abstract][Full Text] [Related]
9. A comparison of two MR hepatobiliary gadolinium chelates: Gd-BOPTA and Gd-EOB-DTPA.
Runge VM
J Comput Assist Tomogr; 1998; 22(4):643-50. PubMed ID: 9676461
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of gadoxetate disodium as a contrast agent for mouse liver imaging: comparison with gadobenate dimeglumine.
Kiryu S; Inoue Y; Watanabe M; Izawa K; Shimada M; Tojo A; Yoshikawa K; Ohtomo K
Magn Reson Imaging; 2009 Jan; 27(1):101-7. PubMed ID: 18599243
[TBL] [Abstract][Full Text] [Related]
11. Dual contrast enhanced magnetic resonance imaging of the liver with superparamagnetic iron oxide followed by gadolinium for lesion detection and characterization.
Kubaska S; Sahani DV; Saini S; Hahn PF; Halpern E
Clin Radiol; 2001 May; 56(5):410-5. PubMed ID: 11384141
[TBL] [Abstract][Full Text] [Related]
12. Conspicuity of liver hemangiomas: short tau inversion recovery, T1, and T2 imaging with gadolinium ethoxybenzyl diethylenetriaminepentaacetic acid.
Brody JM; Schafer L; Tung GA; Breuer J; Shamsi K
J Magn Reson Imaging; 2005 Apr; 21(4):391-7. PubMed ID: 15778951
[TBL] [Abstract][Full Text] [Related]
13. Phantom and animal studies of a new hepatobiliary agent for MR imaging: comparison of Gd-DTPA-DeA with Gd-EOB-DTPA.
Yoshikawa K; Inoue Y; Akahane M; Shimada M; Itoh S; Seno A; Hayashi S
J Magn Reson Imaging; 2003 Aug; 18(2):204-9. PubMed ID: 12884333
[TBL] [Abstract][Full Text] [Related]
14. Current uses of gadolinium chelates for clinical magnetic resonance imaging examination of the liver.
Low RN
Top Magn Reson Imaging; 1998 Jun; 9(3):141-66. PubMed ID: 9621404
[TBL] [Abstract][Full Text] [Related]
15. Dynamic contrast-enhanced magnetic resonance imaging of abdominal solid organ and major vessel: comparison of enhancement effect between Gd-EOB-DTPA and Gd-DTPA.
Tamada T; Ito K; Sone T; Yamamoto A; Yoshida K; Kakuba K; Tanimoto D; Higashi H; Yamashita T
J Magn Reson Imaging; 2009 Mar; 29(3):636-40. PubMed ID: 19243060
[TBL] [Abstract][Full Text] [Related]
16. Multinodular focal fatty infiltration of the liver: atypical imaging findings on delayed T1-weighted Gd-BOPTA-enhanced liver-specific MR images.
Marin D; Iannaccone R; Catalano C; Passariello R
J Magn Reson Imaging; 2006 Sep; 24(3):690-4. PubMed ID: 16878304
[TBL] [Abstract][Full Text] [Related]
17. Tissue gadolinium deposition in renally impaired rats exposed to different gadolinium-based MRI contrast agents: evaluation with inductively coupled plasma mass spectrometry (ICP-MS).
Sato T; Ito K; Tamada T; Kanki A; Watanabe S; Nishimura H; Tanimoto D; Higashi H; Yamamoto A
Magn Reson Imaging; 2013 Oct; 31(8):1412-7. PubMed ID: 23643157
[TBL] [Abstract][Full Text] [Related]
18. Safety and efficacy of a novel hepatobiliary MR contrast agent, Gd-DTPA-DeA: results of phase I and phase II clinical trials.
Tanimoto A; Kadoya M; Kawamura Y; Kuwatsuru R; Gokan T; Hirohashi S
J Magn Reson Imaging; 2006 Apr; 23(4):499-508. PubMed ID: 16534755
[TBL] [Abstract][Full Text] [Related]
19. MR imaging in the evaluation of hepatic metastases.
Imam K; Bluemke DA
Magn Reson Imaging Clin N Am; 2000 Nov; 8(4):741-56. PubMed ID: 11149677
[TBL] [Abstract][Full Text] [Related]
20. Contrast agents in magnetic resonance imaging of the liver: present and future.
Clément O; Siauve N; Lewin M; de Kerviler E; Cuénod CA; Frija G
Biomed Pharmacother; 1998; 52(2):51-8. PubMed ID: 9755795
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
